Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current an ...

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. ORX142 is the second drug candidate from the Compa ...

Centessa Pharmaceuticals (CNTA) FY Conference June 10, 2025 09:20 AM ET Speaker0 Good morning, everyone. Thanks so much for joining us. I'm Andrea Newkirk, one of the biotech analysts at Goldman Sachs, and I'm really pleased to be joined by Saurabh Saha, CEO of Sentessa. Thanks so much for joining us. Speaker1 Thank you, Andrea. Great to be here. Speaker0 Maybe we can start at a high level. Over the last year, you've transitioned fully or almost fully to an orexin focused company. Maybe talk us through your ...

Centessa Pharmaceuticals (CNTA) 2025 Conference June 04, 2025 11:40 AM ET Speaker0 Thank you for sorry. I don't know. It's so loud. Thank you for joining Jefferies Global Healthcare Conference. My name is Kelly Shi, one of the equity analyst on biotech team. And in this fair chat session, we are very pleased to have Mario from Sentosa. And Mario, could you give us an introduction of yourself briefly? Speaker1 Yeah, good morning everybody. Great to be here with you all. Thank you for the invitation, Connie. ...

Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) closed the last trading session at $13.36, gaining 11.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.90 indicates a 138.8% upside potential.The average comprises 10 short-term price targets ranging from a low of $27 to a high of $38, with a standard deviation of $4.01. While the lowest estimate indicates an increase of 102.1 ...

Financial Performance - Centessa Pharmaceuticals reported a license revenue of $15.0 million for the three months ended March 31, 2025, from a license agreement with Genmab[119]. - The net loss for the three months ended March 31, 2025, was $26.1 million, compared to a net loss of $38.0 million for the same period in 2024[118]. - Interest income rose to $7.9 million in Q1 2025, compared to $2.6 million in Q1 2024, indicating improved cash management[118]. - General and administrative expenses decreased to $12.3 million in Q1 2025 from $13.4 million in Q1 2024, primarily due to lower share-based compensation and consulting fees[121]. - Net cash used in operating activities was $57.2 million in Q1 2025, compared to $37.3 million in Q1 2024, reflecting a net loss of $26.1 million[134][135]. - Net cash used in investing activities was $222.4 million in Q1 2025, primarily due to investments in fixed income, compared to a net cash inflow of $16.8 million in Q1 2024[136]. Research and Development - Research and development expenses increased to $33.4 million in Q1 2025, up from $22.7 million in Q1 2024, reflecting a significant investment in clinical programs[118]. - Research and development expenses for Q1 2025 were $33.4 million, up from $22.7 million in Q1 2024, reflecting a $15.4 million increase in costs for the OX2R agonist program[120]. - Centessa Pharmaceuticals is advancing its OX2R agonist program, with ORX750 currently in a Phase 2a study for narcolepsy and other sleep disorders[96][98]. - The company plans to initiate first-in-human studies for ORX142 in 2025, targeting neurological and neurodegenerative disorders[99]. - Centessa discontinued the clinical development of LB101, a LockBody candidate, based on clinical data, while continuing to evaluate the LockBody platform[101]. Funding and Cash Management - The company had cash, cash equivalents, and investments totaling $424.9 million as of March 31, 2025, expected to fund operations into mid-2027[104]. - The company entered into a loan agreement for up to $200 million, receiving $110 million initially, with additional funds available upon achieving certain milestones[126][127]. - The company sold 372,538 ordinary shares under the ATM program in Q1 2025, generating net proceeds of $6.1 million, totaling approximately $36.6 million since the program's inception[131]. - Future funding requirements are expected to increase significantly due to ongoing product development and commercialization efforts[138][139]. Company Classification and Reporting - The company is classified as an emerging growth company, allowing it to delay the adoption of new accounting standards[143]. - The company will remain an emerging growth company until it achieves total annual gross revenues of $1.235 billion or more[144]. - The company is classified as a "smaller reporting company" under the Securities Exchange Act of 1934, allowing it to present only the two most recent fiscal years of audited financial statements in its Annual Report[145]. - As a smaller reporting company, the company has reduced disclosure obligations regarding executive compensation[145]. - The company is not required to provide qualitative and quantitative disclosures about market risk under SEC rules and regulations[146]. License Agreements - A license agreement with Genmab allows access to the LockBody technology platform for research against up to three targets, with Genmab conducting all related R&D activities[102]. - The company expects to incur significant expenses and operating losses as it continues to develop its product candidates and expand its research activities[104].

Exhibit 99.1 Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year BOSTON and LONDON, May 14, 2025 -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the first quarter ended March 31, 2025. "This was a productive quarter for Centessa ...

Operational Challenges - The company has 77 full-time equivalent employees as of March 1, 2025, which may limit its operational capabilities and ability to develop and commercialize programs [198]. - The company implemented a corporate consolidation of its U.S. and UK businesses in mid-2023 to simplify operations and improve efficiency [196]. - The company may face challenges in integrating the operations of its Centessa Subsidiaries, which could expose it to operational and financial risks [194]. - The company may need to divert management's attention to growth activities, impacting day-to-day operations [198]. - The company faces conflicts of interest due to overlapping roles of its officers in both the parent company and its subsidiaries [203]. Financial Position - The company has incurred significant net losses since inception and expects to continue incurring losses for the foreseeable future, with no revenue generated from product sales to date [208]. - As of December 31, 2024, the company had $482.2 million in cash and cash equivalents, expected to fund operations into mid-2027 [217]. - The company anticipates needing substantial additional funds to advance the development of its product candidates, with plans to raise up to $125 million through an Open Market Sale Agreement [216]. - The company faces risks related to its financial position, including the need for additional capital and potential dilution of shareholder value if equity financing is pursued [221][222]. - The company has a limited operating history, making it difficult for investors to evaluate its business and prospects [211]. Product Development and Commercialization Risks - The company may not be successful in developing and commercializing product candidates, which could significantly harm its financial position and adversely affect stock price [189]. - The company has historically relied on independent organizations for regulatory approval and clinical trial management, which presents risks if these services are not available [199]. - A large proportion of the company's value may reside in a limited number of programs, making it vulnerable to adverse developments in those areas [192]. - The company may not be able to attract or execute transactions with subject-matter experts due to its unique asset-centric approach [190]. - The company has terminated several clinical development programs, including the lixivaptan program for ADPKD and the LB101 program for advanced solid tumors, based on strategic evaluations of clinical data [206][207]. Regulatory and Clinical Development Challenges - The company faces risks related to clinical development, including potential delays and failures in obtaining regulatory approvals [237]. - The marketing approval process is expensive and time-consuming, with no guarantee of success, potentially harming the commercial prospects of product candidates [254]. - The company plans to seek initial marketing approval in the United States and major markets in the EU and the UK, but may face challenges in patient enrollment [259]. - Regulatory authorities may impose additional requirements or restrictions that could limit the commercial viability of approved products [252]. - The company is dependent on third parties for accurate data generation and reporting from preclinical studies and clinical trials, which could adversely affect clinical development and commercialization if not compliant [261]. Manufacturing and Supply Chain Risks - Manufacturing processes are complex and may face disruptions due to various factors, including equipment malfunctions and raw material shortages [310]. - The company relies on third-party manufacturers for product candidates, exposing it to risks such as supply chain shortages and quality issues [316]. - The company has not yet manufactured its product candidates on a commercial scale and may face challenges in negotiating favorable terms with outside vendors [316]. - The active pharmaceutical ingredients (API) for certain product candidates are supplied by single-source suppliers, and the loss of any of these suppliers could significantly harm the business [320]. - The company faces risks related to the availability of non-human primates (NHPs) for research, which have been constrained due to global supply issues, leading to increased costs [326]. Intellectual Property Risks - The company must obtain and maintain sufficient patent protection for its product candidates, as failure to do so could allow competitors to develop similar products [327]. - The patent prosecution process is expensive and time-consuming, and the company may not be able to secure necessary patent protections in a timely manner [330]. - The company cannot assure that its product candidates do not infringe on existing patents, increasing the risk of litigation as the biotechnology and pharmaceutical industries expand [336]. - The company may face substantial damages and litigation expenses if found to infringe third-party patents, which could significantly harm its business [341]. - The expiration of patents could open the company to competition from generic medications, adversely affecting its business [366]. Market and Competitive Landscape - The biotechnology and pharmaceutical industries are characterized by rapid technological changes and significant competition, which may hinder the company's ability to market its product candidates effectively [274]. - The potential market for product candidates may be smaller than estimated, adversely affecting financial viability and revenue [384]. - Market acceptance of product candidates will depend on efficacy, safety, cost relative to alternatives, and physician willingness to prescribe [381]. - The company currently has no sales and marketing organization, which could hinder the ability to generate product revenue [386]. - Efforts to educate the medical community on product benefits may require significant resources and may not be successful [387].

Financial Performance - Centessa Pharmaceuticals reported a net loss of $111.3 million for Q4 2024, compared to a net loss of $36.8 million in Q4 2023, and a full-year net loss of $235.8 million for 2024, up from $151.1 million in 2023[9]. - Total revenue for the year ended December 31, 2024, was $6,853,000, compared to $6,853,000 for the year ended December 31, 2023, indicating no growth[16]. - The net loss for the year ended December 31, 2024, was $235,757,000, compared to a net loss of $151,085,000 for the year ended December 31, 2023, reflecting a 56.0% increase in losses[16]. - The loss from operations for the year ended December 31, 2024, was $201,055,000, compared to $171,283,000 in 2023, representing a 17.3% increase[16]. - Interest income for the year ended December 31, 2024, was $14,016,000, up from $10,476,000 in 2023, indicating a 33.0% increase[16]. Research and Development - Research and Development (R&D) expenses for Q4 2024 were $60.9 million, an increase from $29.7 million in Q4 2023, and full-year R&D expenses totaled $150.2 million for 2024, compared to $124.4 million in 2023[9]. - A one-time charge of $31.5 million related to the discontinuation of the SerpinPC program was included in R&D expenses for 2024[9]. - Research and development expenses increased to $150,244,000 for the year ended December 31, 2024, up from $124,405,000 in 2023, representing a 20.7% increase[16]. - The Phase 2a CRYSTAL-1 study of ORX750 is ongoing, with data expected across all three indications (NT1, NT2, and IH) in 2025[9]. - ORX750 demonstrated significant improvement in wakefulness in a Phase 1 study, achieving mean sleep latencies of 38 minutes at the 5.0 mg dose compared to 15 minutes for placebo[6]. - The company plans to present data from the Phase 1 study of ORX750 at the American Academy of Neurology Annual Meeting on April 5, 2025[6]. - ORX142 is advancing through IND-enabling studies, with clinical data expected in 2025, while ORX489 is also in IND-enabling studies[9]. - The company is focused on developing a pipeline of OX2R agonists aimed at treating excessive daytime sleepiness and related symptoms in various disorders[3]. Financial Position - Cash, cash equivalents, and short-term investments amounted to $482.2 million as of December 31, 2024, expected to fund operations into mid-2027[9]. - Total assets increased to $576,798,000 as of December 31, 2024, from $360,246,000 as of December 31, 2023, marking a 60.2% growth[18]. - Cash and cash equivalents rose significantly to $383,221,000 as of December 31, 2024, compared to $128,030,000 in 2023, indicating a 199.4% increase[18]. - Total liabilities increased to $175,253,000 as of December 31, 2024, from $124,002,000 in 2023, which is a 41.2% rise[18]. - Total shareholders' equity increased to $401,545,000 as of December 31, 2024, from $236,244,000 in 2023, reflecting a 69.9% growth[18]. - The weighted average ordinary shares outstanding increased to 132,050,271 for the quarter ended December 31, 2024, compared to 97,923,585 for the same quarter in 2023, reflecting a 34.8% increase[16]. General and Administrative Expenses - General and administrative expenses for Q4 2024 were $13.7 million, compared to $12.3 million in Q4 2023, and full-year expenses were $50.8 million for 2024, down from $53.7 million in 2023[9].

Core Insights - Centessa Pharmaceuticals is advancing its pipeline of OX2R agonists, particularly ORX750, which shows promise in treating excessive daytime sleepiness (EDS) and related disorders [2][4][11] - The company reported significant financial results for Q4 and full-year 2024, including a net loss of $111.3 million for Q4 and $235.8 million for the full year, reflecting increased R&D expenses [11][12] Recent Highlights - The Phase 2a CRYSTAL-1 study for ORX750 is on track, with data expected in 2025 for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) [4][11] - ORX142 and ORX489 are also in IND-enabling studies, with clinical data planned for 2025 [4][11] Financial Results - Cash, cash equivalents, and short-term investments totaled $482.2 million as of December 31, 2024, expected to fund operations into mid-2027 [11] - R&D expenses increased to $60.9 million in Q4 2024 from $29.7 million in Q4 2023, and full-year R&D expenses rose to $150.2 million from $124.4 million [11][12] - General and administrative expenses were $13.7 million for Q4 2024, compared to $12.3 million in Q4 2023 [11][12] - The net loss for Q4 2024 was $111.3 million, up from $36.8 million in Q4 2023, and the full-year net loss increased from $151.1 million in 2023 to $235.8 million in 2024 [11][12] Pipeline and Anticipated Upcoming Milestones - ORX750 is expected to provide data across all three indications in 2025, with a poster presentation scheduled for the AAN Annual Meeting on April 5, 2025 [5][11] - ORX142 and ORX489 are advancing through IND-enabling studies, with clinical data anticipated in 2025 [4][11]